TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Yaron Werber maintains a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $59 to $61.

April 24, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen reaffirms a Buy rating on Ultragenyx Pharmaceutical and increases the price target to $61.
The upgrade in the price target by a reputable analyst like Yaron Werber suggests a positive outlook on Ultragenyx Pharmaceutical's stock, likely due to anticipated performance improvements or positive developments within the company. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100